Facilitated By

San Antonio Medical Foundation

A Randomized Phase 3 Study To Evaluate The Efficacy And Safety Of Enzastaurin Plus R-CHOP Versus R-CHOP In Treatment-Naïve Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess The Novel Genomic Biomarker DGM1

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Research Start Date
Status
Active

The primary objective of this study is to compare the effect of standard of care R-CHOP with enzastaurin versus R-CHOP alone on overall survival in treatment naive, high-risk subjects with Diffuse Large B-Cell Lymphoma who possess the DGM1 biomarker.

Collaborative Project
Clinical Care
Cardiovascular
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.